Navigation Links
Micromet to Present at the 2007 RBC Capital Markets Healthcare Conference on December 12, 2007
Date:12/5/2007

with docetaxel for the treatment of patients with metastatic breast cancer. The third clinical stage antibody is MT293 (formerly D93); also known as TRC093, a first-in-class humanized monoclonal antibody that inhibits angiogenesis and tumor cell growth by binding cleaved collagen. MT293 is licensed to TRACON Pharmaceuticals, Inc. and is being developed in a phase 1 clinical trial for the treatment of patients with cancer and age- related macular degeneration. In addition, Micromet has established a collaboration with Nycomed for the development and commercialization of MT203, Micromet's human antibody neutralizing the activity of GM-CSF, which has potential applications in the treatment of inflammatory diseases, such as rheumatoid arthritis, as well as autoimmune diseases.


'/>"/>
SOURCE Micromet, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Micromet, Inc. to Present at the Sal. Oppenheim 2nd European Healthcare Conference
2. Micromet to Present at the Sachs Associates 7th Annual Biotech in Europe Investor Forum
3. Micromet Data Presented at the International AACR-NCI-EORTC Conference Support the Development of Adecatumumab (MT201) in Earlier Stage Cancer Disease Settings
4. Micromet is Presenting Four Posters on BiTE(R) Antibodies at the International AACR-NCI-EORTC Conference
5. Micromet to Present at the Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference on November 7, 2007
6. Micromet, Inc. Elects Joseph P. Slattery to Board of Directors
7. Imagenetix Inc. to Present at Noble Small Cap Financial Conference on August 21, 2007
8. Avicena Group to Present at Noble Financial Conference
9. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
10. Strategic Diagnostics to Present at Two Upcoming Investor Conferences
11. Intellect Neurosciences, Inc. to Present Data on Alzheimers Vaccine at 13th International Congress of Immunology Conference
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Biology News(10 mins):Moderate weight loss in obese people improves heart function 2Moderate weight loss in obese people improves heart function 3Roe of marine animals is best natural source of omega-3 2More Than One in Five 12 to 17 Year Olds Have Trouble Seeing in Class 53609 1More Than One in Five 12 to 17 Year Olds Have Trouble Seeing in Class 53609 2More Than One in Five 12 to 17 Year Olds Have Trouble Seeing in Class 53609 3More Than One in Five 12 to 17 Year Olds Have Trouble Seeing in Class 53609 4CryoLife Receives CE Mark Approval for BioFoam 28R 29 Hemostatic Technology 53607 1CryoLife Receives CE Mark Approval for BioFoam 28R 29 Hemostatic Technology 53607 2CryoLife Receives CE Mark Approval for BioFoam 28R 29 Hemostatic Technology 53607 3CryoLife Receives CE Mark Approval for BioFoam 28R 29 Hemostatic Technology 53607 4Arcadia HealthCares DailyMed 28TM 29 Signs Deal with Comfort Keepers 28R 29 A Leading Provider of In Home Care 53605 1Arcadia HealthCares DailyMed 28TM 29 Signs Deal with Comfort Keepers 28R 29 A Leading Provider of In Home Care 53605 2Arcadia HealthCares DailyMed 28TM 29 Signs Deal with Comfort Keepers 28R 29 A Leading Provider of In Home Care 53605 3Arcadia HealthCares DailyMed 28TM 29 Signs Deal with Comfort Keepers 28R 29 A Leading Provider of In Home Care 53605 4Arcadia HealthCares DailyMed 28TM 29 Signs Deal with Comfort Keepers 28R 29 A Leading Provider of In Home Care 53605 5